Wan Peng, Yu Wenji, Zhai Lishang, Qian Bo, Zhang Feifei, Liu Bao, Wang Jianfeng, Shao Xiaoliang, Shi Yunmei, Jiang Qi, Wang Mengfei, Shao Shan, Wang Yuetao
Department of Cardiology, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Department of Nuclear Medicine, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Quant Imaging Med Surg. 2024 Feb 1;14(2):1369-1382. doi: 10.21037/qims-23-1129. Epub 2024 Jan 2.
Atrial fibrillation (AF) has been identified to increase stroke risk, even after oral anticoagulants (OACs), and the recurrence rate is high after radiofrequency catheter ablation (RFCA). Inflammation is an essential factor in the occurrence and persistence of AF. F-fluorodeoxyglucose (F-FDG) positron emission tomography/computed tomography (PET/CT) is an established molecular imaging modality to detect local inflammation. We aimed to investigate the relationship between atrial inflammatory activity and poor prognosis of AF based on F-FDG PET/CT.
A total of 204 AF patients including 75 with paroxysmal AF (ParAF) and 129 with persistent AF (PerAF) who underwent PET/CT before treatment were enrolled in this prospective cohort study. Clinical data, electrocardiograph (ECG), echocardiography, and cardiac F-FDG uptake were collected. Follow-up information was obtained from patient clinical case notes or telephone reviews, with the starting point being the time of PET/CT scan. The follow-up deadline was either the date of AF recurrence after RFCA, new-onset stroke, or May 2023. Cox proportional hazards regression models were used to identify predictors of poor prognosis and hazard ratios (HRs) with 95% confidence intervals (CIs) was calculated.
Median follow-up time was 29 months [interquartile range (IQR), 22-36 months]. Poor prognosis occurred in 52 patients (25.5%), including 34 new-onset stroke patients and 18 recrudescence after RFCA. The poor prognosis group had higher congestive heart failure, hypertension, age ≥75 years (doubled), diabetes mellitus, prior stroke or transient ischemic attack (TIA) or thromboembolism (doubled), vascular disease, age 65-74 years, sex category (female) (CHA2DS2-VASc) score [3.0 (IQR, 1.0-3.75) 2.0 (IQR, 1.0-3.0), P=0.01], right atrial (RA) wall maximum standardized uptake value (SUV) (4.13±1.82 3.74±1.58, P=0.04), higher percentage of PerAF [39 (75.0%) 90 (59.2%), P=0.04], left atrial (LA) enlargement [45 (86.5%) 104 (68.4%), P=0.01], and RA wall positive FDG uptake [40 (76.9%) 79 (52.0%), P=0.002] compared with the non-poor prognosis group. Univariate and multivariate Cox proportional hazard regression analysis concluded that only CHA2DS2-VASc score (HR, 1.29; 95% CI: 1.06-1.57; P=0.01) and RA wall positive FDG uptake (HR, 2.68; 95% CI: 1.10-6.50; P=0.03) were significantly associated with poor prognosis.
RA wall FDG positive uptake based on PET/CT is tightly related to AF recurrence after RFCA or new-onset stroke after antiarrhythmic and anticoagulation treatment.
房颤(AF)已被证实会增加中风风险,即便在使用口服抗凝药(OAC)之后亦是如此,并且射频导管消融术(RFCA)后的复发率很高。炎症是房颤发生和持续存在的一个重要因素。F-氟脱氧葡萄糖(F-FDG)正电子发射断层扫描/计算机断层扫描(PET/CT)是一种用于检测局部炎症的成熟分子成像方式。我们旨在基于F-FDG PET/CT研究心房炎症活动与房颤不良预后之间的关系。
本前瞻性队列研究纳入了204例治疗前接受PET/CT检查的房颤患者,其中包括75例阵发性房颤(ParAF)患者和129例持续性房颤(PerAF)患者。收集了临床资料、心电图(ECG)、超声心动图以及心脏F-FDG摄取情况。随访信息通过患者临床病例记录或电话回访获取,起始点为PET/CT扫描时间。随访截止时间为RFCA术后房颤复发日期、新发中风日期或2023年5月。采用Cox比例风险回归模型来确定不良预后的预测因素,并计算95%置信区间(CI)的风险比(HR)。
中位随访时间为29个月[四分位间距(IQR),22 - 36个月]。52例患者(25.5%)出现不良预后,包括34例新发中风患者和18例RFCA术后复发患者。与非不良预后组相比,不良预后组的充血性心力衰竭、高血压、年龄≥75岁(翻倍)、糖尿病、既往中风或短暂性脑缺血发作(TIA)或血栓栓塞(翻倍)、血管疾病、年龄65 - 74岁、性别类别(女性)(CHA2DS2-VASc)评分[3.0(IQR,1.0 - 3.75)对2.0(IQR,1.0 - 3.0),P = 0.01]、右心房(RA)壁最大标准化摄取值(SUV)(4.13±1.82对3.74±1.58,P = 0.04)、PerAF比例更高[39例(75.0%)对90例(59.2%),P = 0.04]、左心房(LA)扩大[45例(86.5%)对104例(68.4%),P = 0.01]以及RA壁FDG摄取阳性[40例(76.9%)对79例(52.0%),P = 0.002]。单因素和多因素Cox比例风险回归分析得出,只有CHA2DS2-VASc评分(HR,1.29;95% CI:1.06 - 1.57;P = 0.01)和RA壁FDG摄取阳性(HR,2.68;95% CI:1.10 - 6.50;P = 0.03)与不良预后显著相关。
基于PET/CT的RA壁FDG阳性摄取与RFCA术后房颤复发或抗心律失常及抗凝治疗后新发中风密切相关。